Dimensional Fund Advisors LP Atreca, Inc. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$0.88 - $1.22 $42,066 - $58,319	-47,803 Reduced 55.07%	38,994 $38,000
Q4 2022 Feb 09, 2023	SELL	$0.78 - $1.68 $7,341 - $15,812	-9,412 Reduced 9.78%	86,797 $69,000
Q3 2022 Nov 10, 2022	BUY	$1.59 - $2.74 $57,688 - $99,412	36,282 Added 60.54%	96,209 $151,000
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $1,968 - $4,101	-1,262 Reduced 2.06%	59,927 $107,000
Q1 2022 May 13, 2022	BUY	$1.61 - $5.2 $2,031 - $6,562	1,262 Added 2.11%	61,189 $194,000
Q4 2021 Feb 09, 2022	SELL	$2.87 - $6.29 $10,966 - $24,034	-3,821 Reduced 5.99%	59,927 $182,000
Q3 2021 Nov 12, 2021	SELL	$4.91 - $9.07 $2,258 - $4,172	-460 Reduced 0.72%	63,748 $397,000
Q2 2021 Aug 12, 2021	SELL	$7.82 - $13.8 $435,292 - $768,163	-55,664 Reduced 46.44%	64,208 $547,000
Q1 2021 May 14, 2021	BUY	$13.0 - $19.34 $1.19 Million - $1.78 Million	91,914 Added 328.76%	119,872 $1.84 Million
Q4 2020 Feb 25, 2021	BUY	$13.03 - $17.09 $364,292 - $477,802	27,958 New	27,958 $452,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.